TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

HUMABODY

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

HUMABODY

ST13

US500000079179556

Class

1, 5, 40, 42

Filing

79179556

Registration

5158366

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

55

Latest update

03/15/2026

Classification

Registered

Trademark type

Word

Nice classes

1, 5, 40, 42

Filing date

12/17/2014

Registration date

03/14/2017

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

06/27/2024

Last transaction

03/15/2026

Responsible office

United States Patent and Trademark Office

Status code

707

Official register

Principal Register

Drawing code

4

Owner type

99

Owner location

Cambridge, GB

Examiner

POLLACK, ALISON FRIEDBERG

Current location

Historical data usage

Holders and representatives

Holders

Crescendo Biologics Limited

Representatives

Rebecca Liebowitz VENABLE LLP

Technical classification

Nice Classes

Class 1Class 5Class 40Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

chemicals used in industry and science; [ chemical test kits for in vitro testing for laboratory research purposes; ] biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments for in vitro scientific and laboratory research use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products

Class 5

pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; veterinary preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; antibody fragments being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases] ; antibody therapeutics in the nature of therapeutic agents for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; medical diagnostic reagents and veterinary diagnostic reagents in the nature of antibodies and antibody fragments; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] and or use in the manufacture of therapeutic products

Class 40

[ Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments ]

Class 42

[ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, drug discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design ]

Publications

History of USPTO decisions and trademark events.

55 publications found

REM4

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED

03/14/2026

INNP

PARTIAL INVALIDATION PROCESSED BY THE IB

06/20/2025

INPS

PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

05/12/2025

INPC

INVALIDATION PROCESSED

05/12/2025

LIMN

LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED

05/12/2025

INPR

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

02/27/2025

RNWL

INTERNATIONAL REGISTRATION RENEWED

12/12/2024

RHRD

RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED

11/08/2024

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

06/27/2024

71.P

REGISTERED - PARTIAL SEC 71 ACCEPTED

06/27/2024

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

05/07/2024

LIMN

LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED

10/27/2023

ES71

TEAS SECTION 71 RECEIVED

09/13/2023

RHRD

RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED

08/19/2023

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

03/14/2022

NREP

NEW REPRESENTATIVE AT IB RECEIVED

12/07/2017

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

07/14/2017

FICS

FINAL DISPOSITION NOTICE SENT TO IB

06/22/2017

FIMP

FINAL DISPOSITION PROCESSED

06/22/2017

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

06/14/2017

R.PR

REGISTERED-PRINCIPAL REGISTER

03/14/2017

ETOP

EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED

02/03/2017

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

11/18/2016

ETOF

EXTENSION OF TIME TO OPPOSE RECEIVED

10/18/2016

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

09/20/2016

PUBO

PUBLISHED FOR OPPOSITION

09/20/2016

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

08/31/2016

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

08/31/2016

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

08/31/2016

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

08/17/2016

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

08/09/2016

XAEC

EXAMINER'S AMENDMENT ENTERED

08/09/2016

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

08/09/2016

GNEA

EXAMINERS AMENDMENT E-MAILED

08/09/2016

CNEA

EXAMINERS AMENDMENT -WRITTEN

08/09/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

08/08/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/08/2016

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

08/08/2016

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

07/29/2016

GNFR

FINAL REFUSAL E-MAILED

07/29/2016

CNFR

FINAL REFUSAL WRITTEN

07/29/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/15/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/15/2016

ALIE

ASSIGNED TO LIE

07/15/2016

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

07/11/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

07/11/2016

RFNT

REFUSAL PROCESSED BY IB

02/01/2016

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

01/11/2016

RFRR

REFUSAL PROCESSED BY MPU

01/11/2016

MAFR

APPLICATION FILING RECEIPT MAILED

01/08/2016

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

01/06/2016

CNRT

NON-FINAL ACTION WRITTEN

01/05/2016

DOCK

ASSIGNED TO EXAMINER

01/04/2016

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/04/2016

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

01/03/2016

Continuous trademark protection

Get notified about every new filing that threatens HUMABODY or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.